QTRX earnings analysis
What we found in QTRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Quanterix delivered Q2 revenue of $32.906 million, approximately 34% above Q2 2025 but below both the $36 million prior-quarter level and $37.529 million consensus. Diluted EPS of negative $1.04 missed the negative $0.38 estimate and worsened year over year. Although adjusted margins and cash usage improved, management lowered 2026 revenue and gross-margin expectations, deferred cash-flow breakeven to 2027, and reduced projected year-end cash to approximately $80 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew year over year but missed estimates
- Q2 revenue was $32.906 million, up approximately 34% from $24 million in Q2 2025, but down from $36 million in Q1 2026 and below the $37.529 million consensus estimate.
- Adjusted profitability improved year over year
- Adjusted gross margin and adjusted EBITDA improved year over year, indicating progress in underlying operating performance despite the reported revenue shortfall.
- Cash usage improved materially
- Adjusted cash usage declined to $3.991 million in Q2, materially better than the $18 million free-cash-flow outflow recorded in Q1 2026.
- Akoya controls integration completed
- Management completed integration of Akoya’s related business processes and systems into the company’s internal controls as of June 30, 2026; Akoya will be included in the annual internal-control assessment for 2026.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes to internal control over financial reporting other than the Akoya integration.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large loss and EPS miss
- Diluted EPS was negative $1.04 versus negative $0.38 consensus and deteriorated from negative $0.77 in Q2 2025, while the company also recorded an Akoya goodwill impairment and a large net loss.
- Revenue outlook was sharply reduced
- 2026 revenue guidance was reduced to $142 million-$148 million from $169 million-$174 million, a reduction of approximately 16%-18% at the midpoint.
- Breakeven delay raises liquidity risk
- Cash-flow breakeven was pushed to 2027, and projected year-end cash was reduced to approximately $80 million from $100 million, increasing liquidity pressure despite Q2 adjusted cash usage of $3.991 million.
- No formal risk-factor changes
- The filing states there were no material changes to the risk factors in the 2025 Form 10-K; however, it notes that litigation can still impose defense and settlement costs and divert management resources even when no proceedings are expected to materially affect financial condition.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.04
What they said about what is next.
2026 revenue guidance was lowered to $142 million-$148 million from $169 million-$174 million; non-GAAP gross-margin guidance was lowered to 48%-50% from 49%-53%. Cash-flow breakeven was deferred to 2027, and projected year-end cash was reduced to approximately $80 million from $100 million.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 6, 2026
- Quanterix Corporation's Q1 2026 results show a 20% year-over-year revenue increase, totaling $36.4 million, despite a slight revenue miss against estimates. The company's EPS improved to -$0.37 from -$0.53 in Q1 2025,…
- 10-K · March 2, 2026
- Quanterix describes a strategy of combining ultra-sensitive Simoa fluid biomarkers with Spatial Biology to drive diagnostics and research adoption, supported by an installed base of over 2,500 instruments and >6,200…
- 10-K · March 17, 2025
- Quanterix positions itself as a leader in ultra-sensitive protein detection with an installed base of over 1,000 Simoa instruments and >3,200 scientific publications, pursuing growth via assay menu expansion (20 new…
- 10-K · March 6, 2023
- Quanterix positions its proprietary ultra-sensitive Simoa platforms as a differentiated, high-sensitivity protein detection franchise with a growing installed base (876 instruments as of December 31, 2022) and broad…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing QTRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever